# Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

> **NCT06869239** · — · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 65 (estimated)

## Conditions studied

- Limited-stage Small Cell Lung Cancer (LS-SCLC)

## Interventions

- **DRUG:** Etoposide + cisplatin/carboplatin
- **RADIATION:** Thoracic radiotherapy
- **RADIATION:** Prophylactic cranial irradiation (PCI)
- **DRUG:** PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT06869239
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-01-03
- **Final completion:** 2028-01-03
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06869239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06869239, "Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06869239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*